NKILA was recently found to be up-regulated by pro-inflammatory cytokines in breast cancer [66], and there is increasing evidence that NKILA can act as an inhibitor of NF-κB in cellular inflammation and regulate the body’s inflammatory response [67]. This evidence concerns the gene NFKB1 and breast carcinoma.